Abstract: Provided are methods for prophylaxis and/or therapy of cancer that include administering to an individual in need thereof an effective amount of a ?-blocker and an immune checkpoint inhibitor such that growth of cancer in the individual is inhibited. Patients include those diagnosed with or at risk for a wide variety of cancer types. Methods are provided for cancer treatment in individuals who are resistant to checkpoint inhibitor monotherapies. Greater than additive anti-cancer effects may be achieved.

Abstract: Provided are methods for prophylaxis and/or therapy of cancer that include administering to an individual in need thereof an effective amount of a ?-blocker and an immune checkpoint inhibitor such that growth of cancer in the individual is inhibited. Patients include those diagnosed with or at risk for a wide variety of cancer types. Methods are provided for cancer treatment in individuals who are resistant to checkpoint inhibitor monotherapies. Greater than additive anti-cancer effects may be achieved.

Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2/neu ECD-PD, ICD and M. tuberculosis antigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.

Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting M. tuberculosis-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or a M. tuberculosis-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with the M. tuberculosis-infected cell.

Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2/neu ECD-PD, ICD and M. tuberculosis antigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.

Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2/neu ECD-PD, ICD and M. tuberculosis antigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.

Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2/neu ECD-PD, ICD and M. tuberculosis antigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.

Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting M. tuberculosis-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or a M. tuberculosis-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with the M. tuberculosis-infected cell.

Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting M. tuberculosis-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or a M. tuberculosis-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with the M. tuberculosis-infected cell.

Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Examples of immunogenic polypeptides include, but are not limited to, her2/neu ICD and M. tuberculosis antigens. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or an infected cell. Included in the invention are T cells produced by this method and a pharmaceutical composition comprising such T cells.

Abstract: A murine model for human breast, ovarian and prostate cancer is provided. The model comprises either an immunodeficient mouse containing human primary breast, ovarian or prostate carcinoma tissue implanted within the gonadal fat pad, or an immunodeficient mouse containing human prostate or ovarian carcinoma tissue subcutaneously implanted therein. Methods of using the murine model, for example, to grow tumors and to screen treatments for breast, ovarian and/or prostate cancer are also provided.

Abstract: A murine model for human ovarian and prostate cancer is provided. The model comprises an immunodeficient mouse containing human primary ovarian or prostate carcinoma tissue implanted within the gonadal fat pad. Methods of using the murine model, for example, to grow tumors and to screen treatments for ovarian and/or prostate cancer are also provided.

Abstract: This invention relates to a flotation immunoassay employing a novel buoyant matrix to which an antigen or antibody is coupled and which separates the bound and free products of the assay by floating to the surface of the reaction liquid. The novel flotation device which makes it possible to detect and to quantitate either antigen or antibody can also be used to fractionate cells and molecules.

Abstract: This invention relates to a carrier for the transport of drugs in a mammalian system comprising milk fat globules.